Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses

Diana F Florescu, Megan A. Keck

Research output: Contribution to journalReview article

54 Citations (Scopus)

Abstract

CMX001 (hexadecyloxypropyl-cidofovir, Brincidofovir) is a broad spectrum, lipid conjugate of cidofovir that is converted intracellularly into the active antiviral, cidofovir diphosphate. The lipid conjugation results in oral bioavailability, higher intracellular concentrations of active drug, lower plasma concentrations of cidofovir and increased antiviral potency against dsDNA viruses.

Original languageEnglish (US)
Pages (from-to)1171-1178
Number of pages8
JournalExpert Review of Anti-Infective Therapy
Volume12
Issue number10
DOIs
StatePublished - Oct 1 2014

Fingerprint

Viruses
Antiviral Agents
Lipids
Diphosphates
Biological Availability
cidofovir hexadecyloxypropyl ester
cidofovir
Pharmaceutical Preparations

Keywords

  • BK virus
  • Brincidofovir
  • CMX001
  • JC virus
  • adenovirus
  • cytomegalovirus
  • dsDNA virus
  • molluscum
  • orthopoxvirus
  • vaccinia virus

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)
  • Virology
  • Infectious Diseases

Cite this

Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses. / Florescu, Diana F; Keck, Megan A.

In: Expert Review of Anti-Infective Therapy, Vol. 12, No. 10, 01.10.2014, p. 1171-1178.

Research output: Contribution to journalReview article

@article{4216f3ca12fa4d2f82f69812ff8b9e20,
title = "Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses",
abstract = "CMX001 (hexadecyloxypropyl-cidofovir, Brincidofovir) is a broad spectrum, lipid conjugate of cidofovir that is converted intracellularly into the active antiviral, cidofovir diphosphate. The lipid conjugation results in oral bioavailability, higher intracellular concentrations of active drug, lower plasma concentrations of cidofovir and increased antiviral potency against dsDNA viruses.",
keywords = "BK virus, Brincidofovir, CMX001, JC virus, adenovirus, cytomegalovirus, dsDNA virus, molluscum, orthopoxvirus, vaccinia virus",
author = "Florescu, {Diana F} and Keck, {Megan A.}",
year = "2014",
month = "10",
day = "1",
doi = "10.1586/14787210.2014.948847",
language = "English (US)",
volume = "12",
pages = "1171--1178",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Expert Reviews Ltd.",
number = "10",

}

TY - JOUR

T1 - Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses

AU - Florescu, Diana F

AU - Keck, Megan A.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - CMX001 (hexadecyloxypropyl-cidofovir, Brincidofovir) is a broad spectrum, lipid conjugate of cidofovir that is converted intracellularly into the active antiviral, cidofovir diphosphate. The lipid conjugation results in oral bioavailability, higher intracellular concentrations of active drug, lower plasma concentrations of cidofovir and increased antiviral potency against dsDNA viruses.

AB - CMX001 (hexadecyloxypropyl-cidofovir, Brincidofovir) is a broad spectrum, lipid conjugate of cidofovir that is converted intracellularly into the active antiviral, cidofovir diphosphate. The lipid conjugation results in oral bioavailability, higher intracellular concentrations of active drug, lower plasma concentrations of cidofovir and increased antiviral potency against dsDNA viruses.

KW - BK virus

KW - Brincidofovir

KW - CMX001

KW - JC virus

KW - adenovirus

KW - cytomegalovirus

KW - dsDNA virus

KW - molluscum

KW - orthopoxvirus

KW - vaccinia virus

UR - http://www.scopus.com/inward/record.url?scp=84907059423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907059423&partnerID=8YFLogxK

U2 - 10.1586/14787210.2014.948847

DO - 10.1586/14787210.2014.948847

M3 - Review article

C2 - 25120093

AN - SCOPUS:84907059423

VL - 12

SP - 1171

EP - 1178

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 10

ER -